Publish in this journal
Journal Information
Vol. 48. Issue 8.
Pages 301 (August 2012)
Vol. 48. Issue 8.
Pages 301 (August 2012)
Letter to the Editor
DOI: 10.1016/j.arbr.2012.05.004
Full text access
Reply
Réplica
Visits
...
Julio Sánchez De Cos Escuína,
Corresponding author
juli1949@separ.es

Corresponding author.
, Jesús Hernández Hernándezb, Marcelo F. Jiménez Lópezc, Susana Padrones Sánchezd, Antoni Rosell Gratacósd, Ramón Rami Portae
a Sección de Neumología, Hospital San Pedro de Alcántara, Cáceres, Spain
b Sección de Neumología, Hospital Ntra. Sra. de Sonsoles, Ávila, Spain
c Servicio de Cirugía Torácica, Hospital Universitario de Salamanca, Salamanca, Spain
d Servicio de Neumología, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
e Servicio de Cirugía Torácica, Hospital Universitario Mutua de Terrassa, Terrassa, Barcelona, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor:

We have read with interest the recent comments about the SEPAR Guidelines for lung cancer staging that refer to the role of PET-CT.1 The authors first suggest initially including for said test those patients who are provisionally classified in stage IIIB, supporting this suggestion with 2 important publications,2,3 one of which was included in the references of the Guidelines.2 Those publications, as well as the SEPAR Guidelines, emphasize optimizing the selection of patients who are candidates for surgery. However, the authors of those studies based their opinions on the latest TNM classification by Mountain, and not on the recent, widely accepted edition of the IASLC.4 In the latter, the inclusion of subgroups T4N0 and T4N1 (some of which, depending on the T4 descriptor, could have a surgical option) in category IIIA (previously considered IIIB) means that the current limit between IIIA and IIIB is much closer to the limit that separates potentially resectable tumors from non-resectable tumors. Therefore, in our opinion, except for under very exceptional circumstances, when given a patient who has already been classified as IIIB by other means (according to the current TNM classification), PET-CT would not make much of a contribution to deciding on surgery. Nevertheless, we do agree with the comments about the potential of PET-CT to better program treatment with thoracic radiotherapy in patients who are candidates. Here, PET-CT may give a more exact definition of the volume to radiate.5

A second aspect commented on by the authors refers to the high diagnostic performance of PET-CT with possible bone metastasis. We completely agree with this as it is expressed in the Guidelines, which also mention the value of PET-CT for detecting possible hidden metastases in uncommon locations. However, we believe that bone scintigraphy, a more economic and universally available procedure (although less effective than PET-CT), is still useful. Often times, when scintigraphy results are interpreted together with a detailed anamnesis and physical examination, some patients are able to be classified in TNM stage IV with a reasonable certainty, which may avoid later tests. We believe that this procedure, which is common in many centers that do not have easy or fast access to PET-CT, is justified by a rational and efficient use of the means that are available. Naturally, this does not mean that it would not be more effective, if resources and delay times are permitting, to directly do a PET-CT.

In closing, we would like to thank the authors for their comments and suggestions, which, undoubtedly, contribute to clarifying the usefulness and the limits of lung cancer staging procedures.

References
[1]
J. Sánchez de Cos, J. Hernández Hernández, M. Jiménez López, S. Padrones Sánchez, A. Rosell Gratacós, R. Rami Porta.
Normativa SEPAR sobre estadificación del carcinoma de pulmón.
Arch Bronconeumol, 47 (2011), pp. 454-465
[2]
G.A. Silvestri, M.K. Gould, M.L. Margolis, L.T. Tanoue, D. McCrory, E. Toloza, et al.
Non invasive staging of non-small cell lung cancer.
Chest, 132 (2007), pp. 178S-201S
[3]
B. Fisher, U. Lassen, J. Mortensen, S. Larsen, A. Loft, A. Bertelsen, et al.
Preoperative staging of lung cancer with combined PET-CT.
N Engl J Med, 361 (2009), pp. 32
[4]
F.A. Shepherd, J. Crowley, P. Van Houtte, P.E. Postmus, D. Carney, K. Chansky, et al.
The International Association for the Study of Lung Cancer. Lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.
J Thorac Oncol, 2 (2007), pp. 1067-1077
[5]
P. Goldstraw, D. Ball, J.R. Jett, T. Le Chevalier, E. Lim, A.G. Nicholson, et al.
Non-small cell lung cancer.
Lancet, 378 (2011), pp. 1727-1740

Please cite this article as: Sánchez De Cos Escuín J, et al. Réplica. Arch Bronconeumol. 2012;48:301.

Copyright © 2012. SEPAR
Idiomas
Archivos de Bronconeumología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.